Inside the pancreas: progress and challenges of human beta cell mass quantification

Area of Science:

• Endocrinology and Metabolism
• Nuclear Medicine Imaging
• Diabetes Pathogenesis

Background:

• Accurate quantification of human beta cell mass is a significant challenge in understanding diabetes.
• Beta cell loss is implicated in both autoimmune (type 1) and type 2 diabetes due to various toxic factors.
• There is a critical need for non-invasive clinical methods for beta cell mass assessment.

Purpose of the Study:

• To validate a novel non-invasive imaging technique for quantifying beta cell mass.
• To assess the potential of (111)indium-labelled exendin-3 SPECT imaging in diabetic models and patients.

Main Methods:

• Utilized single photon emission computed tomography (SPECT) with (111)indium-labelled glucagon-like peptide-1 (GLP-1) receptor agonist exendin-3.
• Correlated SPECT data with morphometric analysis of beta cell mass in a rat model of alloxan-induced diabetes.
• Applied the validated technique to assess beta cell mass in C-peptide-negative type 1 diabetic patients.

Main Results:

• SPECT imaging with (111)indium-labelled exendin-3 showed correlation with direct beta cell mass measurements in a rat model.
• Demonstrated significant beta cell mass loss in C-peptide-negative type 1 diabetic patients.
• The tracer successfully identified reduced beta cell mass.

Conclusions:

• (111)indium-labelled exendin-3 SPECT imaging is a promising tool for non-invasive beta cell mass quantification.
• This technique could facilitate future studies on beta cell loss and regeneration dynamics in larger diabetic cohorts.
• GLP-1-based tracer analysis offers new clinical possibilities for assessing beta cell mass in type 1 diabetes and prediabetes.